Abstract 79P
Background
Perioperative immunotherapy has been shown to be promising option for resectable non-small cell lung cancer(NSCLC). This study aimed to investigate the efficacy and safety of perioperative treatment with tislelizumab (PD-1 inhibitor) plus chemotherapy in resectable stage II-III NSCLC.
Methods
This open-label, single-arm, phase 2 trial planned to enroll 20 patients(pts) with resectable II-IIIB(N2) (AJCC 8th) NSCLC. Pts received neoadjuvant treatment with intravenous tislelizumab combined with chemotherapy Q3W for 2-3 cycles before surgery and 1-2 cycles after surgery (up to 4 cycles perioperative chemotherapy), followed by tislelizumab Q3W for 1 year. Primary endpoints were major pathological response (MPR) rate, the secondary endpoints included pathologic complete response (pCR) rate, objective response rate (ORR), event-free survival (EFS) and overall survival (OS). This study is registered with chictr.org.cn, ChiCTR2300068140.
Results
Between February 2023 and August 2023, 15 pts (median age: 67; male:80%) were enrolled, of whom 66.7% pts had stage III disease, 93.3% pts had squamous cell lung cancer. Among 15 enrolled pts, 5 pts are on neoadjuvant period; 10 pts completed neoadjuvant treatment, and 9 of them underwent surgery with 100% R0 resection. Of 9 pts who underwent resection, 5 pts (55.6%) achieved MPR and pCR. ORR was 63.6%, DFS and OS data was immature. The most common TRAEs were anemia (n=8; 53.3%), and thrombocytopenia (n =5; 33.3%). Most of the TRAEs were grade 1or 2. 3 pts experienced Grade 3 TRAE of WBC count decreased, increased creatine kinase and pneumonia, respectively. No grade 4-5 adverse events were reported.
Conclusions
Tislelizumab combined platinum-based chemotherapy demonstrated high MPR and pCR rate, feasible surgical resection and manageable toxicity in stage II-IIIB NSCLC. Pts will be followed for long-term survival.
Clinical trial identification
ChiCTR2300068140.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - Progression-Free Survival is an acceptable surrogate endpoint for chemo-immunotherapy combinations in Cervical Carcinoma, an EORTC Young GCG study
Presenter: Ramon Yarza
Session: Poster Display
102P - Interim safety analysis of a phase 2 trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer
Presenter: Oladapo Yeku
Session: Poster Display
103P - Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab
Presenter: Saby George
Session: Poster Display
105P - Preliminary efficacy and safety results from ‘ReBirth’, a phase II study of risk-based bladder-sparing therapy for MIBC.
Presenter: Yijun Shen
Session: Poster Display
106P - Treatment Sequencing in PD-L1-Positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Exploratory Analysis of the Phase 3 KEYNOTE-048 Study
Presenter: Amanda Psyrri
Session: Poster Display
108P - Real-world (RW) effectiveness and safety of adjuvant nivolumab (NIVO) in patients (pts) with melanoma in Belgium and Luxembourg: PRESERV MEL
Presenter: Bart Neyns
Session: Poster Display
109P - Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy
Presenter: Inge Noringriis
Session: Poster Display
110P - Outcomes of CUPem: A prospective Phase II multicentre clinical Trial of Pembrolizumab in patients with pre-treated Cancer of Unknown Primary
Presenter: Harpreet Wasan
Session: Poster Display
111P - Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
Presenter: Ciro Celsa
Session: Poster Display